Abstract
At Memorial Sloan Kettering Cancer Center, New York, we have treated over 400 patients with ICE chemotherapy after failure of upfront anthracycline-based therapy with a response rate of 72% in aggressive non-Hodgkin's lymphoma (NHL) and 84% in Hodgkin's disease. Utilizing this database, we have identified pretreatment prognostic markers capable of predicting the quality of response (complete response vs partial response vs failure) to second-line cytoreductive ICE chemotherapy and consequently autologous stem cell transplantation. We have shown that in aggressive NHL, patients achieving a complete response have superior survival when compared to those achieving only a partial response. By identifying a priori those patients destined to have only a partial response to ICE, we will be able to target a group of chemosensitive patients who are most likely to benefit from improved treatment. Novel treatment strategies designed to increase their complete response rate would be anticipated to improve their long-term survival.
Original language | English (US) |
---|---|
Pages (from-to) | S9-S12 |
Journal | Cancer Chemotherapy and Pharmacology, Supplement |
Volume | 49 |
Issue number | 7 |
State | Published - May 23 2002 |
Externally published | Yes |
Keywords
- ICE chemotherapy
- Ifosfamide
- Refractory lymphoma
- Risk-adapted therapy
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Cancer Research